A Phase II Study of 131I-rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)
Status:
Unknown status
Trial end date:
2017-06-01
Target enrollment:
Participant gender:
Summary
Diffuse large B cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma in
Korea. Although there is standard therapy, which is called 'R-CHOP', many obstacles to use
aggressive cytotoxic chemotherapeutic agents such as old age, poor performance status,
refractoriness, and relapsed disease still remains. So we investigate the efficacy of
radioimmunotherapy using 131I-rituximab in refractory or relapsed patients with DLBCL.